Selective internal radiation therapy (SIRT) with yttrium-90 resin microspheres does not improve overall survival (OS) vs sorafenib in patients with locally advanced hepatocellular carcinoma (HCC), although it significantly improves tumour response and reduces adverse events (AEs), the phase III SARAH study has shown.
In patients with liver-only or liver-dominant metastatic colorectal cancer (mCRC) with right-sided primary tumours, addition of selective internal radiation therapy (SIRT) to first-line mFOLFOX6 chemotherapy significantly improves overall survival (OS), according to results of a study presented at the European Society for Medical Oncology (ESMO) 19th World Congress on Gastrointestinal Cancer (WCGC 2017) held in Barcelona, Spain.
Liquid biopsy at disease progression effectively identifies novel and heterogeneous mechanisms of acquired resistance to targeted therapies in patients with a range of gastrointestinal (GI) cancers, which may help guide subsequent therapy.
Asia's trusted medical magazine for healthcare professionals.
Get your MIMS Doctor - Malaysia digital copy today!
Beta-blockers could reduce mortality risk in patients with heart failure with reduced ejection fraction (HFrEF) and moderate or moderately-severe renal dysfunction without causing harm, according to the BB-META-HF* trial presented at ESC 2019.
The US Preventive Services Task Force (USPSTF), in an update of its 2013 recommendations, called on clinicians to offer risk-reducing medications to women who are at increased risk for breast cancer but at low risk for adverse effects.
The use of SGLT-2* inhibitors was not associated with a higher risk of severe or nonsevere urinary tract infections (UTIs) in patients with type 2 diabetes (T2D) compared with DPP**-4 inhibitors or GLP-1*** receptor agonists, a population-based cohort study shows.